

References

L-102

1. 42 CFR 8.12 - Federal opioid treatment standards. 2017.
2. Snyder ML, Fantz CR, Melanson S. Immunoassay-based drug tests are inadequately sensitive for medication compliance monitoring in patients treated for chronic pain. *Pain Physician*. 2017;20(2S):SE1-SE9.
3. Jarvis M, Williams J, Hurford M, et al. Appropriate use of drug testing in clinical addiction medicine. *J Addict Med*. 2017;11(3):163-173.
4. American Society of Addiction Medicine (ASAM). Consensus statement: Appropriate use of drug testing in clinical addiction medicine. 2017.
5. Hayes, Inc. Hayes Medical Technology Directory Report. *Pharmacogenetic and Pharmacogenomic Testing to Improve Outcomes Related to Opioid Use Disorder*. Lansdale, PA: Hayes, Inc; 01/27/2022.
6. Socias ME, Ahamad K, Le Foll B, et al. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale. *Contemp Clin Trials*. 2018;69:21-27.
7. InterQual ® Level of Care Criteria 2021. Acute Care Adult. McKesson Health Solutions, LLC.